.RESEARCH STUDY EMPHASIZE.16 Oct 2024.
In the NIAGARA trial, the enhancement of perioperative durvalumab to basic treatment for muscle-invasive bladder cancer cells enhanced event-free and also on the whole survival, marking a new therapy possibility for this disorder.